Trading Signals: IOVA Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 27, 2023)(Iovance Biotherapeutics Inc)
| IOVA latest price $10.8900 (-0.91%) ($10.7100 - $11.1900) on Wed. Apr. 24, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.19% (three month average) | RSI | 40 | Latest Price | $10.8900(-0.91%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | IOVA declines -0.7% a day on average for past five trading days. | Weekly Trend | IOVA declines -4.7% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Normal for small cap. | Correlated ETFs | Broad market will support IOVA advance at 0% a week (0% probability) IBB(49%) XBI(48%) ARKG(47%) IWO(43%) ARKK(41%) | Factors Impacting IOVA price | IOVA will decline at least -2.095% in a week (0% probabilities). VXX(-13%) VIXM(-8%) UUP(-7%) IFRA(-5%) IDRV(-5%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.095% (StdDev 4.19%) | Hourly BBV | 0 () | Intraday Trend | -1.1% | | | |
|
Resistance Level | $11.01 | 5 Day Moving Average | $10.91(-0.18%) | 10 Day Moving Average | $11.17(-2.51%) | 20 Day Moving Average | $11.01(-1.09%) | To recent high | -13.8% | To recent low | 29.5% | Market Cap | $1.595b | | | | Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA. |